International Assets Investment Management LLC Sells 1,642 Shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC)

International Assets Investment Management LLC lessened its stake in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 21.0% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,186 shares of the company’s stock after selling 1,642 shares during the period. International Assets Investment Management LLC’s holdings in GE HealthCare Technologies were worth $554,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in GE HealthCare Technologies by 14.7% during the third quarter. Vanguard Group Inc. now owns 44,531,402 shares of the company’s stock valued at $3,029,917,000 after buying an additional 5,693,244 shares during the period. Norges Bank purchased a new position in GE HealthCare Technologies in the fourth quarter worth $229,052,000. Capital Research Global Investors grew its holdings in GE HealthCare Technologies by 2.8% in the fourth quarter. Capital Research Global Investors now owns 51,344,719 shares of the company’s stock worth $3,969,975,000 after purchasing an additional 1,401,566 shares during the last quarter. Ameriprise Financial Inc. grew its holdings in GE HealthCare Technologies by 84.4% in the third quarter. Ameriprise Financial Inc. now owns 2,668,695 shares of the company’s stock worth $181,578,000 after purchasing an additional 1,221,436 shares during the last quarter. Finally, Perpetual Ltd purchased a new position in GE HealthCare Technologies in the first quarter worth $96,135,000. Institutional investors own 82.06% of the company’s stock.

Insider Transactions at GE HealthCare Technologies

In other news, CTO Taha Kass-Hout sold 3,300 shares of the business’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $78.70, for a total transaction of $259,710.00. Following the completion of the sale, the chief technology officer now owns 67,300 shares of the company’s stock, valued at $5,296,510. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Jan Makela sold 66,955 shares of the stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $81.54, for a total value of $5,459,510.70. Following the completion of the sale, the chief executive officer now owns 63,348 shares of the company’s stock, valued at approximately $5,165,395.92. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CTO Taha Kass-Hout sold 3,300 shares of the stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $78.70, for a total transaction of $259,710.00. Following the completion of the sale, the chief technology officer now directly owns 67,300 shares of the company’s stock, valued at approximately $5,296,510. The disclosure for this sale can be found here. Insiders sold 90,482 shares of company stock valued at $7,369,137 over the last 90 days. Corporate insiders own 0.27% of the company’s stock.

GE HealthCare Technologies Trading Down 0.3 %

Shares of GE HealthCare Technologies stock opened at $79.17 on Monday. The firm has a 50-day simple moving average of $80.53 and a two-hundred day simple moving average of $81.58. The company has a market cap of $36.14 billion, a P/E ratio of 23.15, a price-to-earnings-growth ratio of 2.86 and a beta of 1.22. GE HealthCare Technologies Inc. has a fifty-two week low of $62.35 and a fifty-two week high of $94.50. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.83 and a current ratio of 1.06.

GE HealthCare Technologies (NASDAQ:GEHC) last released its earnings results on Tuesday, April 30th. The company reported $0.90 EPS for the quarter, hitting analysts’ consensus estimates of $0.90. The business had revenue of $4.65 billion during the quarter, compared to analysts’ expectations of $4.80 billion. GE HealthCare Technologies had a net margin of 8.05% and a return on equity of 25.32%. The company’s quarterly revenue was down 1.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.85 earnings per share. As a group, equities analysts predict that GE HealthCare Technologies Inc. will post 4.27 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have issued reports on GEHC. Citigroup lifted their price target on shares of GE HealthCare Technologies from $88.00 to $103.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Argus boosted their price objective on shares of GE HealthCare Technologies from $80.00 to $110.00 and gave the company a “buy” rating in a report on Monday, April 1st. Mizuho dropped their price objective on shares of GE HealthCare Technologies from $110.00 to $105.00 and set a “buy” rating on the stock in a report on Wednesday, May 1st. Bank of America dropped their price objective on shares of GE HealthCare Technologies from $94.00 to $86.00 and set a “neutral” rating on the stock in a report on Wednesday, May 1st. Finally, Evercore ISI boosted their price objective on shares of GE HealthCare Technologies from $93.00 to $100.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. Five investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $94.09.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.